Boule Diagnostics

Interim report
Q3 2023

Financial Highlights

NET SALES, MSEK
139.6
GROSS MARGIN
41.4
%
OPERATING PROFIT, MSEK
7.9
OPERATIONAL CASH FLOW, MSEK
27.8
DSC5200A (1)

Growth in a challenging market and strengthened operating cash flow

We are delivering good growth in most markets. The strongest growth is in Latin America, where we won a significant strategic order. This order was accepted at a lower price, which puts pressure on the gross margin; on
the other hand, we ensure recurring sales of consumables for many years to come. In Western Europe, we are growing thanks to the start of sales of our new veterinary instrument. In Asia, sales are flat but there is great potential, especially in India. We continue to decline in Eastern Europe as a result of Russia's war in Ukraine. OEM sales of consumables increased by 21 percent in the quarter and have grown by 12 percent in the first nine months.

Net sales by region

Net sales by product

Near-patient diagnostics

Complete Blood Count (CBC) is the most common test for in vitro diagnostics. The decentralized and patient-related hematology segment has an estimated market value of just over SEK 8 billion, while the corresponding segment for the veterinary market is valued at approximately SEK 2.6 billion

Map En

200
+

Distributors in 100 countries

SEK
8
BILLION

Addressable market Human

150
MILLION

Tests per year

ABOUT BOULE DIAGNOSTICS

Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies.